Sharps Technology Inc. - Warrant (OQ:STSSW)
Business Focus: N/A
Mar 07, 2024 08:00 am ET
Sharps Technology and Roncadelle Operations Sign Worldwide Sales and Distribution Agreement for their Innovative Portfolio of Safe Technology Drug Delivery Systems
Sharps Technology, Inc., (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, and Roncadelle Operations, a driving force in the development of novel...
Feb 21, 2024 08:00 am ET
Sharps Technology Enters Latin American Market and Receives First Orders for Securegard Disposable Smart Safety Syringes from Strategic Distribution Partner in Colombia
Sharps Technology, Inc., (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, is preparing to make the first shipment of its 1mL and 3mL Securegard smart...
Feb 16, 2024 02:42 pm ET
Sharps Technology Planning To Collaborate With Roncadelle To Support Global Distribution And Sales Of High Quality, Innovative, Safer Drug Delivery Systems
Sharps Technology, Inc., (NASDAQ: STSS) (NASDAQ: STSSW), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, is working to create new sales and distribution opportunities through the...
Jan 18, 2024 09:00 am ET
Sharps Technology Signs LOI with Roncadelle Operations Intended to Open Worldwide Sales and Distribution Opportunities for Safe Drug Delivery Systems
Sharps Technology, Inc., (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, and Roncadelle Operations, a driving force in the development of novel...
Sep 29, 2023 09:54 am ET
Sharps Technology Announces Closing of $5.6 Million Registered Direct and Private Placement
Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced the closing of its previously announced...
Sep 28, 2023 10:52 am ET
Sharps Technology Issues Letter to Shareholders Covering the Announced Asset Purchase Agreement to Acquire InjectEZ Prefillable Syringe Manufacturing Facility and the Associated $400 Million 10-Year P
Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, issues a shareholder update from Robert Hayes, the Company’s Chief...
Sep 27, 2023 12:03 pm ET
UPDATE - Sharps Technology Announces $5.6 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules
Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced that it has entered into a definitive...
Sep 27, 2023 09:14 am ET
Sharps Technology Announces $5.6 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules
Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced that it has entered into a definitive...
Sep 26, 2023 08:30 am ET
Sharps Technology Signs Asset Purchase Agreement to Acquire InjectEZ Specialty Copolymer Syringe Manufacturing Facility and a 10-Year Purchase Agreement for Over $400 Million from Nephron Pharmaceutic
Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, and Nephron Pharmaceuticals Corporation, (“Nephron”) a...
Jul 12, 2023 08:33 am ET
Sharps Technology Appoints Industry Sales and Manufacturing Leader Ben Scheu as Senior Director of Sales
Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, is pleased to announce the appointment of Ben Scheu as Senior Director...
Jul 06, 2023 07:50 am ET
Sharps Technology Provides Update on Commercialization Activities and is Highlighted in Med Tech Outlook Feature Article
Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, announces an update on commercialization activities and is highlighted...
May 19, 2023 09:00 am ET
Sharps Technology, Inc. and BullFrog AI Holdings, Inc. Interviews to Air on Bloomberg TV on the RedChip Money Report(R)
ORLANDO, FL / ACCESSWIRE / May 19, 2023 / RedChip Companies will air new interviews with Sharps Technology, Inc. (NASDAQ:STSS; STSSW) and BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) on The RedChip Money Report® on Bloomberg TV, this Saturday, May 20, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Apr 04, 2023 08:00 am ET
Sharps Technology Issues Update Letter to Shareholders from CEO Robert Hayes
Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, issues a shareholder update from Robert Hayes, the Company's Chief...
Feb 09, 2023 09:21 am ET
Sharps Technology Appoints Justin Page as Vice President of Technical Operations
Sharps Technology, Inc. (the “Company”, "Sharps") (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, appoints Justin Page as Vice President of Technical...
Feb 06, 2023 09:02 am ET
Sharps Technology Announces Closing of $3.8 Million Private Placement Priced At-the-Market
Sharps Technology, Inc. (the “Company”, "Sharps") (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, today announced that it closed its previously announced...
Feb 01, 2023 09:20 am ET
Sharps Technology Announces Pricing of $3.8 Million Private Placement Priced at the Market
Sharps Technology, Inc. (the “Company”, "Sharps") (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, today announced that it entered into a securities purchase...
Jan 31, 2023 08:00 am ET
Sharps Technology Ships First Containers of Safety Syringes to Nephron Pharmaceuticals for Commercialization
Sharps Technology, Inc. (the “Company”, "Sharps") (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, announces the first shipments of product from its wholly owned...
Jan 10, 2023 08:00 am ET
Sharps Technology Inc. to Introduce New Specialized Prefillable Syringe Systems in 2023
Sharps Technology, Inc. (the “Company”, "Sharps") (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, announces the advancement of the Company's specialized...
Dec 20, 2022 08:00 am ET
Sharps Technology Begins Manufacturing at its Hungary Facility for the Company's Innovative Syringe Products
Sharps Technology, Inc. (the “Company”, "Sharps") (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, announces they have commenced manufacturing of their...
Dec 13, 2022 08:00 am ET
Sharps Technology and Nephron Pharmaceuticals Sign Distribution Agreement for its Innovative Syringe Products
Sharps Technology, Inc. (the “Company”, "Sharps") (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, is pleased to announce the signing of a distribution agreement...
Nov 10, 2022 04:05 pm ET
Nephron Pharmaceuticals Corporation and Sharps Technology, Inc. Announce Manufacturing and Research Partnership
Nephron Pharmaceuticals Corporation and Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery company offering patented, best-in-class syringe products, announced today a new...
Jul 14, 2022 04:05 pm ET
Sharps Technology Completes Acquisition of Safegard Medical Syringe Manufacturing Facility
Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device company offering patented, best-in-class, single use smart safety syringe products, is pleased to announce the Company completed its acquisition of...
Jun 08, 2022 04:05 pm ET
Sharps Technology Announces Letter to Shareholders
Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), is an innovative medical device company offering patented, best-in-class, single use smart safety syringe products, published a letter to shareholders. from Robert Hayes, CEO and...
Apr 19, 2022 09:50 am ET
Sharps Technology, Inc. Announces Closing of $16 Million Initial Public Offering
Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device company offering patented, best-in-class, single use smart safety syringe products, today announced the closing of its initial public offering of...
Apr 13, 2022 09:34 pm ET
Sharps Technology Announces Pricing of Initial Public Offering
Sharps Technology, Inc. (the “Company”), an innovative medical device company offering patented, best-in-class, single use smart safety syringe products, today announced the pricing of its initial public offering of 3,750,000 common units. Each...
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.
